Compound: apomorphine
SMILES: Oc1c2-c3c4c(ccc3)CCN([C@@H]4Cc2ccc1O)C
InChIKey: VMWNQDUVQKEIOC-CYBMUJFWSA-N
Synonyms: apomorphine, 58-00-4, L-Apomorphine, Apomorfin, Apomorphin, Ixense, (-)-Apomorphine, R-(-)-Apomorphine, 6abeta-Aporphine-10,11-diol, Apomorphinum, (-)-10,11-Dihydroxyaporphine, (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, VR-040, N21FAR7B4S, DTXSID8022614, VR040, 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)-, DTXCID302614, CHEBI:48538, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol, (9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol, (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo(de,g)quinoline-10,11-diol, (9R)-10-methyl-10-azatetracyclo(7.7.1.0^(2,7).0^(13,17))heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol, (9R)-10-methyl-10-azatetracyclo(7.7.1.0^(2,7).0^(13,17))heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol, (9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol, Apomorphin Teclapharm, RefChem:56684, (9R)-10-methyl-10-azatetracyclo(7.7.1.02,7.013,17)heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol, 200-360-0, (R)-(-)-Apomorphine, Apomorphine [BAN], CHEMBL53, APL-130277, Apormorphine, (6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol, 6a.beta.-aporphine-10,11-diol, Apomorphine (BAN), NCGC00025349-02, Uprima (TN), (R)?-?(-?)?-?Apomorphine, CAS-58-00-4, Apomorphine free base, 6a-beta-Aporphine-10,11-diol, HSDB 3289, EINECS 200-360-0, UNII-N21FAR7B4S, 58-00-4 (free base), VR004, OR9, VR-400, Apomorphine (R,-), Tocris-2073, APOMORPHINE [MI], Prestwick0_000101, Prestwick1_000101, Prestwick2_000101, Prestwick3_000101, Kynmobi (sublingual film), APOMORPHINE [HSDB], Biomol-NT_000019, GTPL33, APOMORPHINE [VANDF], APOMORPHINUM [HPUS], SCHEMBL8541, APOMORPHINE [WHO-DD], BSPBio_000082, SPBio_002021, BPBio1_000092, BPBio1_001179, SCHEMBL29358024, SCHEMBL29414090, BDBM29644, cid_6852399, (6AR)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL, HMS2089C10, NH001, Tox21_110967, BDBM50001955, EBC-26379, PDSP1_000780, PDSP2_001488, AKOS040740360, Tox21_110967_1, DB00714, FA44559, SMP1_000027, NCGC00025349-01, NCGC00025349-03, NCGC00025349-04, NCGC00025349-05, DA-50067, CS-0012299, D07460, G91374, A727500, AE-641/11399027, EN300-18161186, Q269111, BRD-K76022557-001-01-3, BRD-K76022557-001-03-9, BRD-K76022557-003-02-7, BRD-K76022557-311-20-6, (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, Onapgo (apomorphine hydrochloride for continuous subcutaneous release), (-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(APO), (Apomorphine) 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (apomorphine)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine), (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol (apomorphine), (R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(apomorphine), 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine), 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol((R)-apomorphine), APOMORPHINE6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Theoretical properties:
molecular_formula: C17H17NO2
molecular_weight: 267.32 g/mol
exact_mass: 267.125928785 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 0
heavy_atom_count: 20
topological_polar_surface_area: 43.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Hexagonal plates from chloroform+petroleum ether; rods from ether
color: Hexagonal plates from chloroform+petroleum ether; rods from ether
melting_point: 195 °C (decomposes)
solubility: MINUTE, WHITE OR GRAYISH WHITE, GLISTENING CRYSTALS OR WHITE POWDER; ODORLESS; SOLN ARE NEUTRAL TO LITMUS; LEVOROTATORY IN DIL ACID; 1 G SOL IN 50 ML WATER, IN ABOUT 50 ML ALCOHOL, & IN ABOUT 20 ML WATER @ 80 °C; PPT BY TANNIC ACID & OTHER ALKALOIDAL PRECIPITANTS & DECOMP BY OXIDIZING AGENTS. /HCL/
Descriptions:
{"pubchem": "Apomorphine is an aporphine alkaloid. It has a role as an emetic, a serotonergic drug, an antiparkinson drug, an alpha-adrenergic drug, a dopamine agonist and an antidyskinesia agent. It derives from a hydride of an aporphine.", "chebi": null, "chembl": "APOMORPHINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine that functions as a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and \u03b1-adrenergic receptors with high affinity. The compound is an alkaloid belonging to nymphaea caerulea, or blue lotus, but is also historically known as a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Contrary to its name, apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix relates to it being a morphine derivative (\"[comes] from morphine\").\nHistorically, apomorphine has been tried for a variety of uses, including as a way to relieve anxiety and craving in alcoholics, an emetic (to induce vomiting), for treating stereotypies (repeated behaviour) in farmyard animals, and more recently in treating erectile dysfunction. Currently, apomorphine is used in the treatment of Parkinson's disease. It is a potent emetic and should not be administered without an antiemetic such as domperidone. The emetic properties of apomorphine are exploited in veterinary medicine to induce therapeutic emesis in canines that have recently ingested toxic or foreign substances.\nApomorphine was also used as a private treatment of heroin addiction, a purpose for which it was championed by the author William S. Burroughs. Burroughs and others claimed that it was a \"metabolic regulator\" with a restorative dimension to a damaged or dysfunctional dopaminergic system. Despite anecdotal evidence that this offers a plausible route to an abstinence-based mode, no clinical trials have ever tested this hypothesis. A recent study indicates that apomorphine might be a suitable marker for assessing central dopamine system alterations associated with chronic heroin consumption. There is, however, no clinical evidence that apomorphine is an effective and safe treatment regimen for opiate addiction."}